ScholarLens Back to search
2017•HaematologicaOpen access

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype

Carolina Schinke, Antje Hoering, Hongwei Wang, Victoria E. H. Carlton, Sharmilan Thanandrarajan, Shayu Deshpande, Purvi Patel, Gábor Molnár, Sandra P. Susanibar-Adaniya, Meera Mohan, Pankaj Mathur, Muthukumar Radhakrishnan, Shadiqul Hoque, Jorge Jo Kamimoto, Monica Grazziutti, Frits van Rhee, Maurizio Zangari, Giovanni Insuasti‐Beltran, Daisy V. Alapat, Ginell Ristic Post, Shmuel Yaccoby, Joshua Epstein, Leo Rasche, Sadie Johnson, Martin Moorhead, Tom Willis, Bart Barlogie, Brian A. Walker, Niels Weinhold, Faith E. Davies, Gareth John Morgan

Open full text 34 citations

Abstract

Complete remission (CR) rates for multiple myeloma (MM) have increased to 60% with current treatment approaches, including high dose melphalan-based autologous stem cell transplant (ASCT) and novel agents, and are associated with improved survival.[1][1]–[3][2] Despite this improvement, highly

About this research paper

What this paper is about

Complete remission (CR) rates for multiple myeloma (MM) have increased to 60% with current treatment approaches, including high dose melphalan-based autologous stem cell transplant (ASCT) and novel agents, and are associated with improved survival.[1][1]–[3][2] Despite this improvement, highly

Why it matters

OpenAlex reports 34 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Complete remission (CR) rates for multiple myeloma (MM) have increased to 60% with current treatment approaches, including high dose melphalan-based autologous stem cell transplant (ASCT) and novel agents, and are associated with improved survival.[1][1]–[3][2] Despite this improvement, highly

Key concepts: Multiple myeloma, Melphalan, Oncology, Medicine, Internal medicine, Autologous stem-cell transplantation, Overall survival

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype — Research Paper | ScholarLens